Tags

Type your tag names separated by a space and hit enter

RIMA: a safe concept in the treatment of depression with moclobemide.
Can J Psychiatry. 1992 Sep; 37 Suppl 1:7-11.CJ

Abstract

Moclobemide--a new, safer antidepressant drug--is described and clinical studies are reviewed. Moclobemide represents a new class of drug, the so-called RIMA compounds--reversible inhibitors of MAO-A. Unlike classical monoamine oxidase (MAO) inhibitors, moclobemide is devoid of hepatotoxicity and has only a slight potentiating effect on the hypertensive action of tyramine; treatment does not require a tyramine-restricted diet. Studies comparing moclobemide with tricyclic antidepressants (TCAs) indicate that moclobemide is significantly better tolerated than TCAs and slightly less well tolerated than placebo.

Authors+Show Affiliations

Department of Clinical Research, Neuropsychiatry, F. Hoffmann La-Roche Ltd., Basel, Switzerland.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

1394030

Citation

Amrein, R, et al. "RIMA: a Safe Concept in the Treatment of Depression With Moclobemide." Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, vol. 37 Suppl 1, 1992, pp. 7-11.
Amrein R, Hetzel W, Stabl M, et al. RIMA: a safe concept in the treatment of depression with moclobemide. Can J Psychiatry. 1992;37 Suppl 1:7-11.
Amrein, R., Hetzel, W., Stabl, M., & Schmid-Burgk, W. (1992). RIMA: a safe concept in the treatment of depression with moclobemide. Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie, 37 Suppl 1, 7-11.
Amrein R, et al. RIMA: a Safe Concept in the Treatment of Depression With Moclobemide. Can J Psychiatry. 1992;37 Suppl 1:7-11. PubMed PMID: 1394030.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - RIMA: a safe concept in the treatment of depression with moclobemide. AU - Amrein,R, AU - Hetzel,W, AU - Stabl,M, AU - Schmid-Burgk,W, PY - 1992/9/1/pubmed PY - 1992/9/1/medline PY - 1992/9/1/entrez SP - 7 EP - 11 JF - Canadian journal of psychiatry. Revue canadienne de psychiatrie JO - Can J Psychiatry VL - 37 Suppl 1 N2 - Moclobemide--a new, safer antidepressant drug--is described and clinical studies are reviewed. Moclobemide represents a new class of drug, the so-called RIMA compounds--reversible inhibitors of MAO-A. Unlike classical monoamine oxidase (MAO) inhibitors, moclobemide is devoid of hepatotoxicity and has only a slight potentiating effect on the hypertensive action of tyramine; treatment does not require a tyramine-restricted diet. Studies comparing moclobemide with tricyclic antidepressants (TCAs) indicate that moclobemide is significantly better tolerated than TCAs and slightly less well tolerated than placebo. SN - 0706-7437 UR - https://www.unboundmedicine.com/medline/citation/1394030/RIMA:_a_safe_concept_in_the_treatment_of_depression_with_moclobemide_ L2 - http://www.diseaseinfosearch.org/result/2199 DB - PRIME DP - Unbound Medicine ER -